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Abstract: Glutathione S-transferase (GST) is a superfamily of detoxiﬁ  cation enzymes, 
represented by GSTα, GSTμ, GSTπ, etc. GSTα is the predominant isoform of GST in human 
liver, playing important roles for our well being. GSTπ is overexpressed in many forms of 
cancer, thus presenting an opportunity for selective targeting of cancer cells. Our structure-based 
design of prodrugs intended to release cytotoxic levels of nitric oxide in GSTπ-overexpressing 
cancer cells yielded PABA/NO, which exhibited anticancer activity both in vitro and in vivo 
with a potency similar to that of cisplatin. Here, we present the details on structural modiﬁ  ca-
tion, molecular modeling, and enzymatic characterization for the design of PABA/NO. The 
design was efﬁ  cient because it was on the basis of the reaction mechanism and the structures 
of related GST isozymes at both the ground state and the transition state. The ground-state 
structures outlined the shape and property of the substrate-binding site in different isozymes, 
and the structural information at the transition-state indicated distinct conformations of the 
Meisenheimer complex of prodrugs in the active site of different isozymes, providing guidance 
for the modiﬁ  cations of the molecular structure of the prodrug molecules. Two key alterations 
of a GSTα-selective compound led to the GSTπ-selective PABA/NO.
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Introduction
Glutathione S-transferases (GSTs, EC 2.5.1.18) are a superfamily of enzymes derived 
from distinct gene classes that have been designated α, μ, π, etc. GSTs catalyze the 
conjugation of the sulfur atom of glutathione (GSH) to an electrophilic center of 
endogenous and exogenous compounds, thereby increasing their aqueous solubility for 
subsequent excretion. Being ubiquitous and quite abundant in mammalian tissues, they 
initiate the metabolism of a broad range of alkylating agents and therefore play a central 
role in the detoxiﬁ  cation of many carcinogens as well as anticancer chemotherapeutic 
agents (Jakoby and Habig 1980; Mannervik 1985; Pickett and Lu 1989; Armstrong 
1991, 1994, 1997; Hayes and Pulford 1995; Sheehan et al 2001; Dixon et al 2002). 
Of the superfamily, GSTπ is especially important in cancer therapy because it is often 
expressed at signiﬁ  cantly higher levels in preneoplastic and neoplastic cells (Sato 
et al 1984; Sugioka et al 1985; Suguoka et al 1985; Sato 1988, 1989; Muramatsu et al 
1995). It has also been shown that elevated levels of total GST and overexpression 
of GSTπ often accompany the development of drug resistance in tumors of patients 
undergoing chemotherapy (Morgan et al 1996; O’Brien and Tew 1996; Townsend and 
Tew 2003). Such factors have stimulated recent efforts to target GSTs as a primary 
objective in the discovery of anticancer agents (Flatgaard et al 1993; Lyttle et al 1994; 
Kauvar 1996; Rosario et al 2000; Townsend et al 2002).
We have been trying to turn the GSTπ-overexpression to the tumor’s disadvantage 
by developing PABA/NO [O2-{2,4-dinitro-5-[4-(N-methylamino)benzoyloxy]phenyl}
1-(N,N-dimethylamino)diazen-1-ium-1,2-diolate] that releases the established cytolytic Drug Design, Development and Therapy 2008:2 124
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agent nitric oxide (NO) upon metabolism by GSTπ (Findlay 
et al 2004). PABA/NO belongs to a new family of anticancer 
prodrugs, the O2-aryl diazeniumdiolates (O2ADs), electro-
philic species shown to transfer their aryl groups to attacking 
nucleophiles with cogeneration of ions that spontaneously 
release NO at physiological pH (Saavedra et al 2001). The 
GST-catalyzed GSH addition of PABA/NO proceeds with 
the formation of a Meisenheimer-complex intermediate 
(Figure 1a), and subsequently the leaving group of the reac-
tion releases two moles of NO (Figure 1b). Therefore, within 
the GST-overexpressing cancer cells, the intracellular GSH 
is irreversibly consumed, and the NO thus generated could 
contribute to chemotherapy by inhibiting DNA synthesis, 
forming toxic reactive nitrogen/oxygen intermediates, and 
inhibiting enzymes capable of preventing or repairing cellular 
damage. PABA/NO produces antitumor effects comparable 
with cisplatin in a human ovarian cancer model grown in SCID 
mice and is also potent against proliferation of the OVCAR-3 
cell line (Findlay et al 2004; Saavedra et al 2006). PABA/NO 
is GSTπ-selective, ie, it is more efﬁ  ciently metabolized by 
GSTπ. It was designed on the basis of the mechanism of GST-
catalyzed reaction and the structures of GSTs, especially the 
structural information of GSTs at the transition state.
The attack of GSH on 1-chloro-2,4-dinitrobenzene (CDNB) 
is the basis for the most widely used spectrophotometric 
assay for measurement of GST activity (Habig et al 1974). 
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Figure 1 The Meisenheimer complex. (a) The mechanism of GST-catalyzed reaction of GSH with PABA/NO and with CDNB, showing the formation of the Meisenheimer 
complex as the reaction intermediate. (b) The diazeniumdiolate ion releases two moles of NO at neutral pH. (c) A relatively stable model for the Meisenheimer complex is 
provided by the GSTCD– ion. (d) The GSTμ•GSTCD– structure (PDB entry 4GST). (e) The GSTπ•GSTCD– structure (PDB entry 1AQX). In panels d and e, the protein is 
shown as a molecular surface while the ligand as a stick model in atomic color scheme (carbon in gray, nitrogen in blue, oxygen in red, and sulfur in orange).Drug Design, Development and Therapy 2008:2 125
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As shown in Figure 1a, the reaction proceeds in solution 
via the formation of the Meisenheimer-complex interme-
diate (Miller 1968). Therefore, GST would stabilize the 
Meisenheimer-complex intermediate, at least to the extent 
that the intermediate resembles the transition state for its 
formation. However, the instability of the Meisenheimer 
complex has thus far precluded its structural elucidation. In 
contrast, the reversible reaction of GSH with 1,3,5-trinitro-
benzene (TNB) to form the 1-(glutathion-S-yl)-2,4,6-trinitro-
cyclohexadienate anion (GSTCD–), a potent inhibitor of GST, 
provides a relatively stable model for this intermediate (Clark 
and Sinclair 1988; Graminski et al 1989) as shown in Figure 
1c. To date, crystal structures of the GSTμ•GSTCD– complex 
(PDB entry 4GST; Ji et al 1993) shown in Figure 1d and the 
GSTπ•GSTCD– complex (PDB entry 1AQX; Prade et al 
1997) shown in Figure 1e have been determined, which have 
guided us to model the GSTα•GSTCD– complex. Together, 
the structures and the model played an essential role in our 
structure-based development of PABA/NO.
Structure-based drug design is a growing ﬁ  eld in which 
remarkable advances have been made in recent years 
(Anderson 2003; Scapin 2006). Although the development 
of PABA/NO was brieﬂ  y mentioned previously (Findlay 
et al 2004), the details, involving structural modiﬁ  cation, 
molecular modeling, and enzymatic characterization of 
two key intermediate compounds, have not been reported. 
Besides, the structure of PABA/NO in the previous report 
was not correct (Saavedra et al 2006). Here, we present 
the structure-based design of PABA/NO in detail, during 
which the structures of different classes of GSTs, especially 
the structural information for the transition state of GST-
catalyzed reaction of GSH and CDNB, played an essential 
role. With this unique example, we demonstrate again the 
importance of structure-based approach in drug development 
and the value of structural information for the transition 
state of an enzyme-driven reaction in structure-based drug 
design.
Materials and methods
Structural modiﬁ  cations of O2AD 
molecules
Figure 2 depicts our structural modiﬁ  cations starting from 
GSTα-selective compounds 1 and resulting in GSTπ-
selective compound 4 (PABA/NO). Compounds 1, 2, and 3 
were prepared as previously described (Saavedra et al 2001), 
as was compound 4 (Findlay et al 2004).
Modeling the GSTα•GSTCD– complex
Molecular modeling studies were carried out on an SGI Fuel 
workstation with program packages CNS and O (Jones and 
Kjeldgaard 1997; Brünger et al 1998). The initial model of 
GSTCD– bound to GSTα was built on the basis of the crystal 
structures of the GSTCD– found in the active sites of GSTμ 
(PDB entry 4GST), and GSTπ (PDB entry 1AQX), and then 
it was docked into the active site of GSTα in complex with the 
GSH adduct of ethacrynic acid (PDB entry 1GSE; Cameron 
et al 1995). The model complex, built in dimeric form because 
GSH interacts with the side chains from both subunits, was 
subject to geometry optimization using the conjugate gradient 
method by Powell embedded in CNS (Powell 1977; Brünger 
et al 1998). The Engh and Huber geometric parameters were 
used as the basis of the force ﬁ  eld (Engh and Huber 1991). 
The coordinates of the GSTα•GSTCD– model (Figure 3a) are 
available from the corresponding author upon request.
Modeling GST with bound Meisenheimer 
complex of O2AD
The initial models of the Meisenheimer complex of compounds 
1 and 4 (GS1– and GS4–) bound to the three GST isozymes were 
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Figure 2 Structure-based design of PABA/NO. Structural modiﬁ  cations of the GSTα-selective compounds 1 and 2 have led to the GSTπ-selective compound 4 (PABA/NO).Drug Design, Development and Therapy 2008:2 126
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built on the basis of the crystal structures of compounds 1 and 4 
(Saavedra et al 2001, 2006) and the GSTCD– structures in the 
GSTα•GSTCD– model, the GSTμ•GSTCD– structure (PDB 
entry 4GST), and the GSTπ•GSTCD– structure (PDB entry 
1AQX). The initial models of GS2– were derived from those 
of GS4– by removing the 5-position bulky group, and then they 
were docked into the active sites of the corresponding GSTs. The 
dimeric model complexes, except for GSTπ•GS1– (Figure 4c) 
and GSTα•GS4– (Figure 4g), were subject to geometry optimiza-
tion in the same manner as for the GSTα•GSTCD– complex.
Kinetic studies
The recombinant GST isoenzymes were either purchased 
from Panvera or puriﬁ  ed as described previously (Zimniak 
et al 1994). The reaction mixture, in a ﬁ  nal volume of 1 mL, 
contained 0.1 M phosphate buffer (pH 6.5–7.0), 1–5 μg/mL of 
the desired GST protein, 1–2 mM GSH and varying concentra-
tions of compound 1 or compound 2 (20–200 μM). Change in 
absorbance was monitored spectrophotometrically at 380 nm. 
The enzyme activity was calculated using an extinction coef-
ﬁ  cient of 3.58 mM-1 cm-1. Kinetic parameters were calculated 
using the Michaelis-Menten equation by software KiNET 
(Kinexus, Vancouver, Canada). The experiments were repeated 
three times and the results were averaged.
The same set of kinetic studies was carried out in two inde-
pendent laboratory settings and the results were consistent.
Illustrations
The schematic illustrations for the crystal structures and the 
models were generated with PyMOL (DeLano 2002).
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Figure 3 The GSTα•GSTCD– model. (a) Stereoview showing the GSTα•GSTCD– model, constructed on the basis of the crystal structure of GSTα in complex with the 
GSH conjugate of ethacrynic acid (PDB entry 1GSE), the GSTμ•GSTCD– structure (PDB entry 4GST), and the GSTπ•GSTCD– structure (PDB entry 1AQX). The protein is 
shown as a molecular surface while the ligand as a stick model in atomic color scheme (carbon in gray, nitrogen in blue, oxygen in red, and sulfur in orange). (b) Stereoview 
showing the alignment of the GSTCD– ions in the GSTα•GSTCD– model, in the GSTμ•GSTCD– structure (PDB entry 4GST), and in the GSTπ•GSTCD– structure (PDB entry 
1AQX). The GSTCD– ion is shown as a stick model in atomic color scheme (nitrogen in blue, oxygen in red, and sulfur in orange; carbon in green when bound in GSTα, cyan 
in GSTμ, and magenta in GSTπ).Drug Design, Development and Therapy 2008:2 127
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Results and discussion
Structure of a transition-state analog 
in complex with GSTα
GSTα is the predominant isoform of GST in human liver, 
whereas GSTπ is most abundant in extrahepatic tissues and is 
overexpressed in many types of tumors. In order to target tumor 
cells while avoiding toxicity to the liver, structural informa-
tion is needed for GSTα in complex with the transition-state 
analog GSTCD–. On the basis of available structural informa-
tion, we have built a model of the GSTα•GSTCD– complex 
(Figure 3a). Together, the GSTμ•GSTCD– structure (PDB 
entry 4GST), the GSTπ•GSTCD– structure (PDB entry 
1AQX), and the GSTα•GSTCD– model have shown that the 
conformation of the GSTCD– ion exhibits such dramatic 
differences when it is bound in the active site of different 
GSTs that the aromatic ring of the GSTCD– ion stretches out 
in distinct directions (Figure 3b), providing the guidance for 
our structure-based modiﬁ  cation of O2AD molecules toward 
the GSTπ-selective PABA/NO.
Compound 1 is GSTα-selective
Compound 1 (Figure 2) is the ﬁ  rst O2AD molecule we 
have ever synthesized (Saavedra et al 2001). All three 
classes of GSTs catalyze the NO release of 1. However, 
it is GSTα-selective, 2-fold over GSTμ and 145-fold over 
GSTπ (Table 1). To understand the structural basis for the 
different catalytic efﬁ  ciencies, we have constructed model 
complexes of the three GSTs with GS1–, the Meisenheimer 
complex of 1. The models of GSTα•GS1– (Figure 4a) 
and GSTμ•GS1– (Figure  4b) suggest favorable interac-
tions between the protein and the reaction intermediate. 
The GSTπ•GS1– model, however, suggests unfavorable 
interaction between the diethyl group of the diazenium-
diolate moiety and the protein (Figure 4c). Therefore, the 
ﬁ  rst modiﬁ  cation of 1 was to replace the diethylamino 
group of the diazeniumdiolate moiety with a dimethyl-
amino group, which was predicted to improve the ﬁ  t of the 
reaction intermediate derived from the resulting compound 
to GSTπ.
Compound 2 indicates that our design 
is on the right track
As expected, compound 2 (Figure 2) is indeed a better sub-
strate for GSTπ than compound 1. The catalytic efﬁ  ciency 
of GSTπ toward 2 exhibits a noticeable increase (Table 2), 
which is likely due to the reduced steric interactions between 
the diazeniumdiolate moiety of the reaction intermediate and 
the protein (Figure 4c). Moreover, the two other GSTs are 
less active toward 2, with a 4-fold reduction in the catalytic 
efficiency for GSTα and a 3-fold reduction for GSTμ 
(Table 2). Although it is not as obvious, the reduction of the 
hydrophobic interactions between the protein and the diaze-
niumdiolate moiety of GS2–, the Meisenheimer complex of 2, 
may have played a role. Although 2 is still GSTα-selective, 
1.5-fold over GSTμ and 24-fold over GSTπ, the improvement 
has indicated that our structure-based design is on the right 
track. The next modiﬁ  cation is to further reduce the GSTα 
selectivity while increasing the GSTπ selectively.
We have constructed model complexes of GS2– with 
GSTα (Figure 4d), GSTμ (Figure 4e), and GSTπ (Figure 4f). 
The models suggest that the addition of a sterically 
demanding constituent at position 5 of the aryl ring should 
increase its accommodation in the active site of GSTπ 
(Figure 4f) while decreasing its accommodation in the active 
site of GSTα (Figure 4d). Thus, compound 3 was designed 
and synthesized (Figure 2). Unfortunately, the solubility 
of 3 was too low, rendering its enzymatic characterization 
impossible. Further modiﬁ  cation aimed to improve the 
solubility has led to the synthesis of compound 4, ie, the 
PABA/NO (Figure 2).
PABA/NO (Compound 4) 
is GSTπ-selective
As expected, PABA/NO (compound 4) is a better substrate 
for GSTπ compared to GSTα (Findlay et al 2004). The model 
of GSTα in complex with the Meisenheimer complex of 4 
(GSTα•GS4–) suggests unfavorable interaction between the 
bulky group at position 5 of the aryl ring system (Figure 4g). 
In contrast, both GSTμ and GSTπ can accommodate this 
Table 1 Kinetic data for human GST isoenzymes with Compound 1 as the variable substrate
Enzymea Km (μM) Vmax (nmol min−1 mg−1) kcat (s−1) kcat/Km b (mM−1 s−1)
GSTα 196 ± 63 200898 ± 37633 171 872
GSTμ 171 ± 51 85508 ± 14322 73 427
GSTπ 523 ± 143 4017 ± 848 3.1 6
Notes: aMolecular weight used for calculation of kcat: GSTα, 51000 Da; GSTμ, 51160 Da; GSTπ, 46000 Da; bCatalytic efﬁ  ciency.Drug Design, Development and Therapy 2008:2 128
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group (Figure 4, panels h and i). Thus, the structure-based 
modiﬁ  cations of 1 have reversed the GST isoenzyme selec-
tively of O2AD.
GSTμ activity toward O2AD
The expression of GSTμ is null in 50% of the human popu-
lation due to a gene deletion (Rowe et al 1997). Therefore, 
our current effort has been focused on GSTα and GSTπ 
while keeping GSTμ in the scope of our investigation for 
better understanding the reaction mechanism. Strategies 
have been developed to avoid GSTμ for the development of 
next-generation O2AD anticancer prodrugs.
The Meisenheimer complex of O2AD
We have previously shown that the transient Meisenheimer 
complex is generated in the reaction of compound 1 
(Saavedra et al 2001). On the basis of this mechanism, 
during which the Meisenheimer complex of O2AD is formed 
(Figure 1a), we have used the GSTμ•GSTCD– structure 
(Figure 1d), the GSTπ•GSTCD– structure (Figure 1e), and 
the GSTα•GSTCD– model (Figure 3a) to guide the construc-
tion of the three GSTs in complex with the Meisenheimer 
complex of O2ADs (Figure 4).
The model complexes of GST with the Meisenheimer 
complexes of O2AD have played a crucial role in guiding 
Table 2 Kinetic data for human GST isoenzymes with Compound 2 as the variable substrate
Enzymea Km (μM) Vmax (nmol min−1 mg−1) kcat (s−1) kcat/Km
b (mM−1 s−1)
GSTα 136 ± 27 37932 ± 3793 32 237
GSTμ 1910 ± 327 337169 ± 53003 287 150
GSTπ 237 ± 404 2997 ± 404 2.2 9.7
Notes: aMolecular weight used for calculation of kcat: GSTα, 51000 Da; GSTμ, 51160 Da; GSTπ, 46000 Da; bCatalytic efﬁ  ciency.
1 2 4 (PABA/NO)
GSTπ
GSTμ
GSTα
Figure 4 Models of the three GST isozymes with bound Meisenheimer complex of compound 1, 2, and 4. The GST active sites are illustrated as non-transparent surfaces, 
except for a transparent surface in panels c and g to show the unfavorable interaction between the ligand and the protein (indicated with red arrows), and the ligands as stick 
models in atomic color scheme (carbon in green, nitrogen in blue, oxygen in red, and sulfur in orange).Drug Design, Development and Therapy 2008:2 129
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the modiﬁ  cation of compounds 1 and 2, resulting in the 
development of compound 4, the GSTπ-selective PABA/
NO as an anticancer drug lead. The key factors in this 
design include (1) understanding the difference in the 
shape and property of the substrate-binding site of different 
GSTs and (2) using the structures of GSTCD– in different 
GST complexes to guide the molecular modeling. For 
example, the substrate-binding site is broad in both GSTμ 
and GSTπ (Figure1 panels d and e). However, it is virtu-
ally a hydrophobic cavity in GSTμ, but is approximately 
half hydrophobic and half hydrophilic in GSTπ (Ji et al 
1997). It is mainly the property of the binding site that 
dictates the orientation of the trinitrophenyl ring system 
of GSTCD– in these two isoenzymes. In support of this 
notion, the ring system of the GSH adduct of phenanthrene 
9,10-oxide also points into opposite directions in these two 
isoenzymes (Ji et al 1994, 1997). Unlike GSTμ and GSTπ, 
GSTα has a narrower substrate-binding site, which limits 
the conformational freedom of the trinitrophenyl moiety 
of GSTCD– (Figure 3a).
Conclusions
This paper describes the details on structural modiﬁ  cation, 
molecular modeling, and enzymatic characterization 
for structure-based design of PABA/NO. The design 
was efﬁ  cient because it was on the basis of the reaction 
mechanism and the structures of related GST isozymes at 
both the ground state and the transition state. The ground-
state structures outlined the shape and property of the 
substrate-binding site in different isozymes, and the known 
transition-state structures helped us build a model of GSTα 
at the transition state of which the structural information was 
not available. The structural information thus derived for 
the transition state, showing distinct conformations of the 
Meisenheimer complex of O2ADs in the active site of dif-
ferent isozymes, guided the modiﬁ  cations of the molecular 
structure of O2AD molecules. Two key alterations of a 
GSTα-selective compound, the reduction of the size of the 
amino group and the introduction of the bulky group, led 
to the GSTπ-selective PABA/NO.
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